Novartis Ag

Organisation

Lichtstrasse 35, Basel, Switzerland, 4056

Headquarters

75267

Employees

Health Technology

Industry

Vasant Narasimhan

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Price

Target

Novartis Ag (NVS) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Novartis Ag (NVS) share price will touch around $146 in next 12-months.

Currently 32 wall-street analysts regularly analyze the financials of Novartis Ag on a frequent basis to provide recommendations along with target share price. 32 analysts offering 12-month price forecasts for Novartis Ag (NVS) have a share price target of $146. This median of share price forecast represents a -1.43% downside from the latest price of $148.12 as on 24.03.26.

Novartis Ag (NVS) Share Price Forecast

Home

US Stocks

Novartis Ag (NVS)

Novartis Ag Stock Forecast

Novartis Ag Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Novartis Ag (NVS): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Novartis Ag's share price and its median forecast price. As on 24.03.26, the difference is -4.38%

Novartis Ag Forecast and Target Price

Novartis Ag (NVS) Share Price Forecast

Novartis Ag (NVS) Price vs Consensus Price Target

Novartis Ag (NVS) Share Price Forecast v/s Share Price Today

Novartis Ag (NVS): Difference between Current Price & Median Forecasted Price

Novartis Ag (NVS) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price